[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"YSLab\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,58],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100641585","clinical-evaluation-of-the-efficacy-of-a-nasal-spray-in-the-treatment-of-nasal-dryness-100641585",false,"NCT07657247","Clinical Evaluation of the Efficacy of a Nasal Spray in the Treatment of Nasal Dryness","Clinical Evaluation of the Efficacy of a Nasal Spray Based on Isotonic Seawater and Hyaluronic Acid in the Treatment of Nasal Dryness","Inclusion Criteria:\n\n* Gender: female and\u002For male.\n* Age: adults and children from 6 years old:\n* The physician's score for at least two symptoms, in addition to a dry nose, must average at least 2 at the enrolment visit (Day 0), for a minimum total score of 6.\n* Subjects agree to refrain from taking any medication and\u002For taking any action to relieve nasal symptoms throughout the study, from Day -4 to Day 7, apart from acetaminophen.\n* Autonomous adult, or minor with the consent of their legal representative.\n* Subject and\u002For Parent\u002Flegal guardian of the subject has given freely and expressly her\u002Fhis informed consent.\n* Subject and\u002For Parent\u002Flegal guardian is cooperative and aware of the necessity and duration of the controls so that perfect adhesion to the protocol established by the clinical trial center could be expected.\n* Ability of the patient (for adults) or their legal representative (for children) to follow the instructions for product use.\n* Having signed a free and informed consent to participate in the study expressed by the patient (for adults) or by their legal representative (for children) after being informed by the doctor.\n\nExclusion Criteria:\n\n* Subjects taking anticoagulants, antihistamines, nonsteroidal anti-inflammatory drugs (NSAIDs), or topical or systemic decongestants within two weeks prior to Visit 1 and during the study.\n* Subjects using other nasal sprays, nasal pumps, nasal irrigation\u002Frinsing devices, or oils, creams, or gels in the nose within two weeks prior to Visit 1 and during the study.\n* Subjects with a history of sensitivity to products related to the product being evaluated.\n* Subjects with any clinically significant comorbid condition that, in the opinion of the principal investigator, could affect the subject's safety and\u002For participation in the study.\n* Person whose ability to use the product daily and complete the daily follow-up diary is in doubt.\n* Person refusing to sign the informed consent form prior to the study.\n* Person participating or having participated in any other clinical study within the 30 days preceding the study.\n* Person participating in any other clinical study.","ALL","6 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to see whether the nasal spray can help improve hydration of the nasal mucosa, reduce discomfort linked to nasal dryness, and confirm its safety in patients suffering from nasal dryness.",[26],"Nasal Dryness","NOT_YET_RECRUITING","2026-06-12",{"date":30,"type":31},"2026-06-18","ACTUAL",{"date":33,"type":20},"2026-12-15",{"date":35,"type":20},"2027-03",{"name":37,"class":38},"YSLab","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":24,"conditions":49,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":4},"100608638","evaluation-of-a-medical-device-based-on-isotonic-seawater-and-hyaluronic-acid-used-as-a-nasal-spray-100608638","NCT07204158","Evaluation of a Medical Device Based on Isotonic Seawater and Hyaluronic Acid Used as a Nasal Spray","Clinical Performance Evaluation of a Medical Device Based on Isotonic Seawater and Hyaluronic Acid Used as a Nasal Spray in Children and Adults With Nasal Dryness: a Prospective, Multicentric, Non-randomized Study in Real-life Conditions.","Inclusion Criteria:\n\n* IC1. Male, female over 6 years old.\n* IC2 Rhinoscopy score of at least 6, with a dryness symptom score of at least 2.\n* IC3. Have a smartphone that can use MILO application, for any patient that wishes to answer the questionnaires on their phone.\n* IC4. Patient and\u002For parent\u002Flegal guardian can understand and comply with protocol requirements and instructions.\n* IC5. Patient willing to not change their daily habits including but not limited to Smoking, use of fireplace candles, air conditioning, cold air, medication and dehumidifier.\n* IC6. Signed informed consent (by patient and\u002For parent\u002Flegal guardian).\n\nExclusion Criteria:\n\n* EC1. Patients taking anticoagulants, over-the-counter or prescription systemic\u002Ftopical corticosteroids, antibiotics, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), leukotriene antagonists, topical or systemic decongestants or any treatment for relieve of nasal symptoms (except acetaminophen) in the two weeks prior to Visit 1 and during the study;\n* EC2. Patient with known hyper sensibility to the study treatment;\n* EC3. Patients using other nasal sprays, nasal pumps, nasal irrigation\u002Fwashing devices or nasal oils, creams or gels in the two weeks prior to Visit 1 and during the study;\n* EC4. Patients with any dermatological, respiratory or medical condition (e.g., asthma, pneumonia, laryngotracheobronchitis, sinusitis, nasal polyposis and chronic sinusitis, urticaria or eczema) that, in the opinion of the principal investigator, could interfere with the interpretation of study results;\n* EC5. Patients with a positive medical history of any significant illness in the 2 weeks preceding the study, which, in the opinion of the principal investigator, could interfere with the interpretation of study results;\n* EC6. Patients with nasal anatomical anomalies, e.g., severely deviated septum, congenital cleft lip\u002Fpalate, nasal hemorrhagic diathesis (assessed by principal investigator);\n* EC7. Patient that uses cocaine or other inhaled drugs\n* EC8. Patients with any clinically significant co-morbid condition that, in the opinion of the principal investigator, could interfere with the interpretation of study results;\n* EC9. Enrolled in another clinical trial or being in a period of exclusion from a previous clinical trial;\n* EC10. Women of childbearing age (except menopausal, hysterectomized, and sterilized) are not using effective contraception (oral contraceptives, intra-uterine devices, contraceptive implants, or condoms);\n* EC11. A person belonging to a population referred to in articles 64 (incapacitated subjects), 66 (pregnant or breastfeeding women), 67 (persons performing mandatory military service, persons deprived of liberty, persons who, due to a judicial decision) and 68 (patients in an emergency) of the MDR 2017\u002F745.",{"count":47,"type":20},65,[23],[26],"2025-10-02",{"date":52,"type":31},"2025-10-08",{"date":54,"type":20},"2025-10-07",{"date":56,"type":20},"2026-02-28",{"name":37,"class":38},{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100554419","efficacy-of-two-nasal-products-based-on-diluted-seawater-in-the-treatment-of-upper-respiratory-infectionsconditions-100554419","NCT06498843","Efficacy of Two Nasal Products Based on Diluted Seawater in the Treatment of Upper Respiratory Infections\u002FConditions","Clinical Evaluation of the Effectiveness of Nasal Pump Spray Medical Devices DM004 and DM020 Based on Diluted Seawater in the Treatment of Colds, Rhinitis, Sinusitis, and Other Upper Respiratory Infections\u002FConditions","Inclusion Criteria:\n\n* Autonomous adult, or minor with the consent of their legal representative\n* Adults and children from 3 months old\n* Ability of the patient (for adults) or their legal representative (for children) to follow the instructions for product use\n* Having signed a free and informed consent to participate in the study expressed by the patient (for adults) or by their legal representative (for children) after being informed by the doctor.\n* Person with an upper respiratory tract infection (cold, rhinitis, rhinopharyngitis…) with symptoms of nasal congestion and nasal discharge of moderate to severe intensity (Jackson derived score (nasal congestion + nasal discharge) ≥ 4 on Day 0).\n* Persons with symptoms that started no more than 48 hours before the first visit\n\nExclusion Criteria:\n\n* Person not showing cold symptoms, particularly no nasal congestion (chronic dry rhinitis, or Jackson derived score (nasal congestion + nasal discharge) \\< 4 on Day 0).\n* Person undergoing treatment with a cortisone derivative, mucolytic, or medication containing pseudoephedrine or a similar product acting on nasal congestion or having used such a product within the 3 days preceding inclusion.\n* Person having used a nasal wash product within the 3 days preceding inclusion.\n* Person whose ability to use the product daily and complete the daily follow-up diary is in doubt.\n* Person refusing to sign the informed consent form prior to the study.\n* Person participating or having participated in any other clinical study within the 30 days preceding the study.\n* Person participating in any other clinical study.","3 Months",{"count":67,"type":20},91,[23],"The goal of this interventional clinical trial is to test the safety and efficacy of two medical devices in subjects aged from 3 months old for the treatment of colds, rhinitis, sinusitis, and other upper respiratory infections\u002Fconditions for 7 days.",[71,72,73,74],"Rhinitis","Sinusitis","Upper Respiratory Infections","Colds","2024-07-31",{"date":77,"type":31},"2024-08-02",{"date":79,"type":20},"2025-01",{"date":81,"type":20},"2025-06",{"name":37,"class":38},""]